Table 6

Potential risks and limitations of plasma and prothrombin complex concentrate (PCC) therapy for warfarin-associated coagulopathy

ProductRisks and limitations
Single-donor plasma 

  1. Longer time to administer

  2. Volume constraints

  3. Transmissible disease, known/unknown

  4. Transfusion-related acute lung injury

 
PCC 

  1. Limited availability

  2. Some preparations lack factor VII

  3. Donor pools: 3000-20 000

  4. Transmissible disease, known/unknown (new variant Jakob-Creutzfeldt disease [nvCJ], hepatitis A, parvovirus B19)

  5. Thrombogenicity

 
ProductRisks and limitations
Single-donor plasma 

  1. Longer time to administer

  2. Volume constraints

  3. Transmissible disease, known/unknown

  4. Transfusion-related acute lung injury

 
PCC 

  1. Limited availability

  2. Some preparations lack factor VII

  3. Donor pools: 3000-20 000

  4. Transmissible disease, known/unknown (new variant Jakob-Creutzfeldt disease [nvCJ], hepatitis A, parvovirus B19)

  5. Thrombogenicity

 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal